<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765193</url>
  </required_header>
  <id_info>
    <org_study_id>19-175 ex 07/08</org_study_id>
    <nct_id>NCT00765193</nct_id>
  </id_info>
  <brief_title>The Impact of Total Body Skin Examination on Skin Cancer Detection</brief_title>
  <acronym>TBSE</acronym>
  <official_title>The Impact of Total Body Skin Examination on Skin Cancer Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a study where all patients will undergo a two-step procedure:

      Step 1 - Physicians examine the problem area of skin ONLY and record result. Step 2 -
      Physicians perform TBSE and record result. Eventual lesions suggestive of melanoma and
      non-melanoma skin cancers will be recorded after step 1 or step 2 examination and will be
      finally biopsied and histopathologically diagnosed. Exceptions to biopsy may include patients
      with multiple non-melanoma skin cancers (e.g. actinic keratoses or basal cell carcinomas).

      Each center will be provided with an electronic data sheet for patients record, or
      alternatively, with a paper record form.

      Endpoints of the study are new parameters concerning the standard of care for skin cancer
      screening. We expect to conclude that TBSE enables clinicians discovering an increased number
      of skin cancers thus resulting in earlier detection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinicans performed a two-step examination for skin cancer, with clinical examination of
      individual lesions was aided by the use of dermoscopy, as needed. In the first step,
      physicians performed inspection of problem areas and uncovered areas only, and lesions
      suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was
      performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin
      cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the
      biopsied or excised lesions.

      Statistical analysis: We calculated absolute risks as the proportion of individuals with the
      target disease divided by all individuals at risk. The number needed to examine was
      calculated by dividing the individuals at risk by the numbers of individuals with the target
      disease. Confidence intervals for proportions were calculated using standard formulas based
      on the binomial distribution. Chi square tests were used for comparison of proportions.

      Continuous variables are presented as mean and standard deviation (SD) unless otherwise
      specified. For univariate and multivariate analyses we used odds ratios derived from logistic
      regression to estimate relative risks and their confidence intervals. All p-values reported
      are 2-tailed. Statistical significance is defined as P &lt;0.05. Statistical analysis was
      performed using SPSS software, version 16.0 (SPSS, Chicago, Ill, US).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether a Systematic Screening is Related to a Higher Number of Unnecessary Excisions of Benign Skin Tumors Detected During the Screening.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14381</enrollment>
  <condition>Melanoma</condition>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Skin cancer screening</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inspection of covered areas</intervention_name>
    <description>Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.</description>
    <arm_group_label>Skin cancer screening</arm_group_label>
    <other_name>Inspection of problem areas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive, unselected adult (18 years or more) patients with any skin disorders.
             Skin disorder must be localized on a limited body area and should NOT require total
             body skin examination (TBSE) to be diagnosed and/or treated.

        Exclusion Criteria:

          -  Patients who ask for or need TBSE as the main reason for consultation. A patient must
             be also excluded if a significant part of the body should be undressed for diagnosis
             and/or treatment (i.e. if the shirt or trousers should be removed for diagnosis and/or
             treatment, then the patient must be excluded).

          -  patients under the age of 18 years.

          -  patients who do not agree to get TBSE.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Hofmann-Wellenhof, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Argenziano, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz-Austria: Department of Dermatology</name>
      <address>
        <city>Graz</city>
        <zip>8046</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>June 27, 2009</results_first_submitted>
  <results_first_submitted_qc>April 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2010</results_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Rainer Hofmann-Wellenhof</name_title>
    <organization>Department of Dermatology; Medical University of Graz-Austria</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Skin Cancer Screening</title>
          <description>Physicians examine, first, the problem area of skin and record result, and second, the full body and record result.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Problem Area Examination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Full Body Examination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Skin Cancer Screening</title>
          <description>Physicians examine, first, the problem area of skin and record result, and second, the full body and record result.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14381"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body.</title>
        <time_frame>one year</time_frame>
        <population>From a population of patients with various skin conditions, participants were considered for inclusion only if aged 18 years or more, and if suffering from focused skin complaints. Patients with diffuse skin complaints were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Problem Area Examination</title>
          </group>
          <group group_id="O2">
            <title>Full Body Examination</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body.</title>
          <population>From a population of patients with various skin conditions, participants were considered for inclusion only if aged 18 years or more, and if suffering from focused skin complaints. Patients with diffuse skin complaints were excluded.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14381"/>
                <count group_id="O2" value="14381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="810"/>
                    <measurement group_id="O2" value="631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary outcomes were the calculation of the absolute and relative risks of missing a skin cancer when TBSE is not performed, as well as the number of patients needed to examine by TBSE to find a skin cancer. The secondary outcome was to assess the magnitude of false-positive results obtained by TBSE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.12</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Whether a Systematic Screening is Related to a Higher Number of Unnecessary Excisions of Benign Skin Tumors Detected During the Screening.</title>
        <time_frame>one year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse events were collected for this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Skin Cancer Screening</title>
          <description>Physicians examine, first, the problem area of skin and record result, and second, the full body and record result.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Iris Zalaudek, MD</name_or_title>
      <organization>Department of Dermatology, Medical University of Graz-Austria</organization>
      <phone>+436763328269</phone>
      <email>iris.zalaudek@medunigraz.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

